{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:14:29Z","timestamp":1788570869357,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","award":["P01-CA066996-19"],"award-info":[{"award-number":["P01-CA066996-19"]}],"id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","award":["P50-CA100707-15"],"award-info":[{"award-number":["P50-CA100707-15"]}],"id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["CA134807"],"award-info":[{"award-number":["CA134807"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["CA137123"],"award-info":[{"award-number":["CA137123"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["CA179062"],"award-info":[{"award-number":["CA179062"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.celrep.2021.108870","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:18:07Z","timestamp":1616087887000},"page":"108870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Xiaohong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tint","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Meads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima Ahmed","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satishkumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariosto S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M.","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2021.108870_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2021.108870_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional Addiction in Cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2021.108870_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.celrep.2021.108870_bib7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2021.108870_bib8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2021.108870_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2013.12.011","article-title":"Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma","volume":"25","author":"Colomer","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2021.108870_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.celrep.2021.108870_bib12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.celrep.2015.12.094","article-title":"Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4\/6 Inhibition Elicits Unique Vulnerabilities","volume":"14","author":"Franco","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2021.108870_bib14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.4161\/cc.6.16.4554","article-title":"P-TEFb is a crucial co-factor for Myc transactivation","volume":"6","author":"Gargano","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.celrep.2021.108870_bib15","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1021\/cr400105n","article-title":"RNA polymerase II transcription elongation control","volume":"113","author":"Guo","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.celrep.2021.108870_bib16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2010.04.013","article-title":"HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription","volume":"38","author":"He","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib17","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","article-title":"Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia","volume":"125","author":"Hing","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2021.108870_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib19","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","article-title":"HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma","volume":"128","author":"Jacobson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2021.108870_bib20","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2021.108870_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.15079","article-title":"Venetoclax as a single agent and in combination with PI3K-MTOR1\/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma","volume":"184","author":"Jiang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.celrep.2021.108870_bib22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.celrep.2021.108870_bib49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nature Methods"},{"issue":"3","key":"10.1016\/j.celrep.2021.108870_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/bioinformatics\/bty648","article-title":"Scaling read aligners to hundreds of threads ongeneral-purpose processors","volume":"35","author":"Langmead","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2021.108870_bib24","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib25","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2021.108870_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.1630","article-title":"GREAT improves functional interpretation of cis-regulatory regions","volume":"28","author":"McLean","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.celrep.2021.108870_bib27","doi-asserted-by":"crossref","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","article-title":"Enrichment map: a network-based method for gene-set enrichment visualization and interpretation","volume":"5","author":"Merico","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.celrep.2021.108870_bib28","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1200\/JCO.2020.38.15_suppl.8055","article-title":"Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with Ibrutinib resistance","volume":"38","author":"Nomie","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2021.108870_bib29","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.celrep.2021.108870_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","article-title":"Controlling the elongation phase of transcription with P-TEFb","volume":"23","author":"Peterlin","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib32","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1172\/JCI122533","article-title":"PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas","volume":"128","author":"Ren","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2021.108870_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","article-title":"Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression","volume":"8","author":"Rusan","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2021.108870_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/2159-8290.CD-15-1283","article-title":"Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2021.108870_bib35","first-page":"e53070","article-title":"An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells","author":"Silva","year":"2015","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.celrep.2021.108870_bib36","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","article-title":"An Ex\u00a0Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma","volume":"77","author":"Silva","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2021.108870_bib37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1101\/gad.2015411","article-title":"The super elongation complex (SEC) and MLL in development and disease","volume":"25","author":"Smith","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2021.108870_bib38","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2021.108870_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2021.108870_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","article-title":"Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4","volume":"19","author":"Yang","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","article-title":"Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex","volume":"7","author":"Zawistowski","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2021.108870_bib43","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2021.108870_bib44","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","article-title":"Cutting Edge: ROR1\/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.celrep.2021.108870_bib45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00018-019-03209-y","article-title":"Metabolic reprogramming of normal oral fibroblasts correlated with increased glycolytic metabolism of oral squamous cell carcinoma and precedes their activation into carcinoma associated fibroblasts","volume":"77","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.celrep.2021.108870_bib46","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2021.108870_bib47","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2021.108870_bib48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1056\/NEJMe1307596","article-title":"Toward new treatments for mantle-cell lymphoma?","volume":"369","author":"Zucca","year":"2013","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124721001844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124721001844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:15:43Z","timestamp":1761909343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124721001844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2211124721001844"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2021.108870","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2021.108870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"108870"}}